| dc.description |
Micro/nanomotors have emerged as promising platforms for various applications, including drug delivery and controlled release. These tiny machines, built from nanoscale materials such as carbon nanotubes, graphene, metal nanoparticles, or nanowires, can convert different forms of energy into mechanical motion. In the field of medicine, nanomotors offer potential for targeted drug delivery and diagnostic applications, revolutionizing areas such as cancer treatment and lab-on-a-chip devices. One prominent material used in drug delivery is hyaluronic acid (HA), known for its biocompatibility and non-immunogenicity. HA-based drug delivery systems have shown promise in improving the efficacy and reducing the toxicity of chemotherapeutic agents like doxorubicin (DOX). Additionally, micro/nanomotors controlled by external stimuli enable precise drug delivery to specific areas of the body. Cold atmospheric plasma (CAP) has also emerged as a promising technology for drug delivery, utilizing low-temperature plasma to enhance drug release and bioavailability. CAP offers advantages such as localized delivery and compatibility with various drug types. However, further research is needed to optimize CAP drug delivery systems and understand their mechanisms. In this study, gold-hyaluronic acid (Au-HA) micromotors were synthesized for the first time, utilizing acoustic force for self-motion. The release profile of DOX, a widely used anticancer drug, was investigated in pH-dependent conditions, and the effect of CAP on drug release from the micromotors was examined. Following exposure to the CAP jet for 1 min, the micromotors released approximately 29 μg mL−1 of DOX into the PBS (pH 5), which is significantly higher than the 17 μg mL−1 released without CAP. The research aims to minimize side effects, increase drug loading and release efficiency, and highlight the potential of HA-based micromotors in cancer therapy. This study contributes to the advancement of micro-motor technology and provides insights into the utilization of pH and cold plasma technology for enhancing drug delivery systems. |
|